Abstract
remains a difficulty because of unavailability of laboratory tests that accurately show changes in both procoagulant and anticoagulant systems. International Normalized Ratio, which is widely used as 'the' test for liver related coagulopathy and protein synthetic dysfunction, is a poor marker in acute and chronic liver disease states [1] . In-depth knowledge regarding the pathophysiology of hemostasis in liver disease is of utmost importance for holistic management of end stage liver disease related coagulopathy. End stage liver disease is characterized by features of decompensation such as conjugated hyperbilirubinemia, ascites development, gastrointestinal haemorrhage, hepatic encephalopathy, renal dysfunction, endogenous infections and coagulopathy. Coagulopathy in the setting of liver disease is defined as an INR > 1.5. Hemostatic defect in chronic liver disease is complex, involving opposing factors of primary hemostasis, coagulation, and fibrinolysis [2] . Even though causal relationship between coagulopathy of liver disease with bleeding is a widely accepted practice, sometimes, this is not completely balanced in the clinical scenario. A common practice is to treat or prevent bleeding with blood products and other agents such as freshfrozen plasma, platelet concentrates, antifibrinolytic drugs, prothrombin complex concentrates and recombinant activated factor VII [3] . The ability of these agents and products to improve or correct the homeostatic abnormality has not been validated in randomized trials. Recent research has challenged this practice as well as the usefulness of conventional tests in assessment of bleeding risk as well as therapeutic interventions aimed at correcting abnormal haemostasis. The clotting process is a dynamic which involves phases of platelet plug initiation and formation, coagulation cascade activation, antithrombotic mechanisms that curb clotting progression thereby striking a balance and ultimately, clot fibrinolysis after stabilization. The liver plays a central role in each of these processes and in In order to avoid excessive quantities of thrombin that is potentially harmful, the natural anticoagulants come into control play. These compounds are located in the vascular endothelium. The most important of them are tissue factor pathway inhibitors (TFPI), antithrombin and protein C. TFPI binds to the TF-factor VIII complex to prevent activation of factors IX and X. Antithrombin acts directly on thrombin but also acts on factors IXa and Xa. Circulating Protein C needs thrombomodulin by which it acts as a receptor during activation of thrombin and which joins with an endothelial receptor [endothelial protein C receptor (or EPCR)]. This results in the transformation of protein C into activated protein C, which in presence of cofactor protein S, inhibits factors V and VIII [7] . Available testing for coagulation poorly explains the changes that occur locally and is more concerned with systemic coagulopathic changes such as seen in disseminated intravascular coagulation (DIC). A brief overview of the role of platelets, the coagulation cascade and clot formation and fibrinolysis in the normal environment is shown in Figure 2 . 
Platelets and Liver Disease
In liver disease, all phases of hemostasis are deranged in the presence of synthetic dysfunction and portal hypertension (portosystemic shunting and endothelial dysfunction).Compensatory mechanisms come into play at this point and lead to rebalancing of the coagulation system whereby patients of end stage liver disease are less prone to spontaneous bleeding or clotting in the absence of specific trigger (such as acute variceal bleeding or systemic infections). Platelets are considered central to coagulopathy of liver disease and primary hemostatic derangement has been the focus of liver related bleeding/clotting diathesis [8] . In chronic liver disease, there is a decrease in number of circulating platelets along with thrombocytopathy (platelet dysfunction). This is considered to be multifactorial, which includes pooling of platelets and sequestration in the spleen, presence of antiplatelet glycoprotein IIb-IIIa antibodies in cirrhosis patients, myelosuppression, shorter half-life and rapid turnover secondary to splenic destruction, increased platelet consumption secondary to sustained low grade DIC and lower levels of hepatic thrombopoetin production [9] . Qualitative defects in platelet function also prevail in cirrhosis patients. In the presence of endothelial injury, under normal circumstances, platelet adherence to endothelium is mediated by von Willebrand factor (vWF), a large molecular weight glycoprotein that gets activated when cleaved by endothelial derived protease ADAMTS13. In liver disease, in the presence of endothelial dysfunction, vWF levels are elevated in proportion to disease severity. Even though simulated studies of platelet function in cirrhosis patients have shown increased adherence of platelets to endothelial surfaces in the presence of exaggerated vWF levels, such compensatory mechanisms fail to modify injury in the presence of thrombocytopenia. It has been shown that the thrombin burst required for plug stability warrants a minimum of 50,000 to 60,000 platelets per cumm of blood. Other qualitative defects that are described includes acquired storage pool defects such as decreased adenosine triphosphate and serotonin in dense granules, altered transmembrane signal transduction, decreased thromboxane A2 synthesis, quantitatively decreased glycoprotein Ib, Ia and IIb3 receptors, decreased response to thrombin, adenosine monophosphate, arachidonic acid and collagen [10] . Platelet dysfunction is also dependent on lower haematocrit levels seen in patients of cirrhosis.The extrinsic factors like abnormal high density lipoprotein and apolipoprotein E levels and increased levels of endothelium derived nitric oxide and prostacyclin (which are platelet inhibitors) also add to platelet dysfunction in cirrhosis; this dysfunction is also augmented in the presence of concomitant renal dysfunction and sepsis or drug related additive effect. Even though platelet dysfunction plays a central role in coagulation abnormality of liver disease, there is a weak correlation between bleeding time, platelet count and bleeding risk in patients of cirrhosis [11] . The clinical relevance of thrombocytopenia and hypoaggregability in cirrhosis remains elusive. Platelet reduction in cirrhosis is mostly mild to moderate and there is no strong association with severe bleeding in patients with stable liver disease. Platelet function, as measured by ability for thrombin generation is mostly maintained in patients of stable cirrhosis in whom the platelet counts and haematocrit are well within normal range. 
Coagulation Cascade and Liver Disease
Cirrhosis is characterized by reduction in synthesis of procoagulant proteins especially those that are vitamin K dependant such as II, VII, IX and X; as well as factor V and factor XI [13] .
These factor abnormalities affect standard coagulation measures available in clinical practice, mainly PT and INR, thereby making these parameters substandard for defining coagulopathy in the presence of cirrhosis. Factor V and Factor VII have the shortest in vivo half-lives (12 and 4-6 h, respectively) and are the most decreased procoagulants in patients with liver disease.Vitamin K deficiency in chronic liver disease maybe due to poor nutrition or malabsorption caused by decreased bile production or biliary obstruction. Vitamin K deficiency is defined as low plasma vitamin-K1 levels measured by reverse-phase high performance liquid chromatography but do not correlate with the vitamin-K deficiency prevalence when PT prolongation is used as a surrogate marker, and therefore this parameter
should not be assumed to be a reliable marker of vitamin K deficiency in patients with chronic liver disease. PT is dependent on Factor VII levels and since Factor VII has the shortest in vivo half-life, an isolated prolonged PT is common for patients with liver disease. Even though more than 6% of the normal activity level of a given coagulation factor is enough to prevent spontaneous bleeding, this single factor coagulation deficiency model may not be applicable to cirrhosis, in which almost every coagulation factor is deficient [14] . Currently, no significant correlation has been found between fibrinogen concentration, PT prolongation, factor V activity and bleeding tendency clinical markers such as melena, hematemesis, gastric ulcer bleeding, persistent skin bleeding after liver biopsy, menorrhagia, positive fecal occult blood test and blood transfusion requirements [15] . Factor VIII, which is synthesized in the liver and endothelial cells and vWF which is present in endothelial cells, platelets and megakaryocytes are also acute phase reactants and hence normal or elevated factor VIII and vWF levels may be found in cirrhotic patients caused by continued endothelial cell Factor VIII production despite decreased hepatic FVIII production and increased synthesis caused by acute disease or inflammation. Even in the presence of decreased procoagulant factors and abnormal PT/INR values, cirrhosis patients do not spontaneously bleed mostly due to the fact that there is a concomitant decrease in anticoagulant factors such as protein C, protein S and antithrombin III (attributed to decreased hepatocyte function, increased consumption due DIC or hyperfibrinolysis, and vitamin K deficiency) with additive effect from increased endothelial derived factor VIII. This promotes rebalancing of the hemostatic system in proportional to the severity of the disease. TAFI levels were found to be an independent predictor of mortality after correction for age, sex, aetiology of cirrhosis, and CTP class [18] . prophylactic administration of antibiotics has been shown to reduce the bleeding risk. Renal failure in the form of hepatorenal syndrome and acute kidney injury frequently complicates liver disease, which also aggravates hemostatic abnormalities. Uremia is well known to be associated with disturbed platelet-vessel wall interaction and intrinsic platelet abnormalities, enhanced production of nitric oxide and anemia [19] . Even though laboratory evidence of hypocoagulation such as a prolonged PT/APTT has been long associated with cirrhosis patients, there has been an assumption that these patients are protected against thrombotic disease. On the contrary, the intravascular activation of coagulation may occur much more frequently. It has been shown that patients with liver disease do develop deep vein thrombosis and pulmonary embolism at rates between 0.5% and 1.9%. Large population-based studies have confirmed that patients with liver disease are at increased risk for development of venous thrombosis compared with healthy persons. Liver-related thrombosis events such as thrombosis of the portal and mesenteric veins, is common in patients with advanced cirrhosis.
Change in portal hemodynamics (such as decreased portal flow) is one important factor that plays a major role in this thrombotic complication [20] . Inherited thrombophilias, in particular the prothrombin G20210A mutation, enhances the risk for portal vein thrombosis in patients with cirrhosis. Hence approaches to diagnosing liver related thrombosis must include a thorough evaluation of underlying primary thrombophilic states [21] . Hepatic artery thrombosis which is more often seen after liver transplantation has been recently implicated secondary to hypercoagulation of liver disease rather than a surgical complication.
Intrahepatic thrombus formation has been demonstrated in patients with cirrhosis and also in patients with acute liver failure. The presence of these microthrombi are believed to play a key role in progression of fibrosis as a result of local ischemia, a process referred to as parenchymal extinction. Additionally, the activation of hepatic stellate cells by thrombin may also contribute to the progression of disease. Factor VII, soluble tissue factor and fibrinogen, as well as platelet hyperaggregability and endothelial dysfunction. Thus NAFLD is clearly associated with a prothrombotic state, which is reflected in a substantially increased incidence of thrombotic events in patients with NAFLD , rather than bleeding [22] .
Rebalanced Hemostasis as A Clinical Concept (Figure 3)
Patients of liver disease, especially cirrhosis are prone to both bleeding and thrombotic risks.
In a very simplistic model, the occurrence of bleeding complications has been explained by thrombocytopenia, thrombocyte dysfunction, decreased plasma levels of coagulation factors and decreased plasma levels of inhibitors of fibrinolysis. Thrombotic disease has been attributed to decreased plasma levels of the natural anticoagulants protein C and S and antithrombin. In patients with liver disease, in whom extremely complex alterations of hemostasis occur, reliability on the levels of individual coagulation factors, or on simplified tests of hemostasis such as the PT or APTT to predict the hemostatic status is arguable. These simple tests are extremely helpful in diagnosing and monitoring patients with isolated defects of cirrhosis is not only explained by a reduction in both pro-and anticoagulants, but also by a marked resistance to the inhibitory action of thrombomodulin. The fibrinolytic system may also be in balance in patients with cirrhosis, due to the concomitant decrease of antifibrinolytics such as antiplasmin, thrombin activatable fibrinolysis inhibitor and plasminogen. Overall, the hemostasis is rebalanced due to simultaneous alterations in both pro-and antihemostatic processes, although routine laboratory tests of hemostasis would still suggest a hypocoagulable state [23] . This hemostatic balance is easily disturbed by complications of the disease including infections and renal failure. Although the hemostatic balance is preserved in patients with cirrhosis, in individual patients, the balance may fall toward either a hypo-or hypercoagulable status, explaining why both bleeding and thrombotic episodes occur. There is a possibility that detailed clinical assessment by standardized bleeding scores or thrombosis risk assessment be able to identify those cirrhosis patients who are at risk for either bleeding or thrombosis, but this has not been validated yet. In patients with liver disease, major surgical procedures, including liver transplantation may be performed without major bleeding complications, even in the absence of correction of underlying coagulopathy, which is definitely not possible in conditions of isolated coagulation disorder. This further proves that the hemostatic dysfunction in cirrhosis patients, is 'stable anomaly' rather than a simple clinical derangement [24] . Randomized controlled clinical trials (RCT), which compared a policy of restrictive transfusions to that with a liberal transfusions in cirrhosis patients undergoing LT and in those patients of acute variceal bleed found that the former policy lead to a significant reduction in adverse effects. 
Hemostasis During Liver Transplantation
Dysfunctional hemostasis occurring during LT is divided as a correlate to the surgical pahses.
These include dissection or preanhepaticphase, anhepatic phase, post-reperfusion phase and early post-operative period [25] . In the anhepatic phase, no important surgical blood loss is usually seen because of appropriate clamping of vessels. But, significant haemostatic changes may occur nonetheless.
Platelets and coagulation factors are depleted by surgical bleeding together with the absence of the hepatic synthetic and clearance function. The release of tissue thromboplastin and the absence of the hepatic clearance of activated coagulation factors may cause excessive activation of coagulation. There is gradual increase in thrombin-antithrombin-III complex and fibrin degradation products. The presence of clinically significant intravascular coagulation or thrombosis is usually rare in this phase. There is also a simultaneous decrease of α2-antiplasmin and plasminogen activity along with the concomitant increase in fibrin and fibrinogen degradation products. There occurs no changes in PT and PTT. The reperfusion of the liver is a crucial point in this major surgery and usually leads to profound coagulation abnormalities. Indeed, diffuse and uncontrollable bleeding may occur in some patients within minutes after reperfusion. This effect is multifactorial and has been identified as DIC, hyperfibrinolysis, platelet activation, trapping of platelets in the graft, and the presence of heparin-like effect. The poor quality of the graft has been associated with signs of DIC after graft reperfusion. There occurs release and washout of plasminogen activators from the graft which is responsible for the increased levels of tPA at reperfusion heparin like substances are sourced from the residual heparin bound to the endothelium of the donor vessels, as the donor liver is perfused with heparin before clamping. Apart from this, there is also an endogenous source of heparinoids that are thought to occur from activation of macrophages following the ischemia reperfusion injury. Platelets also have a role in haemostatic abnormalities during this phase. After reperfusion, the platelet count decreases by 30% to 55% because of entrapment of platelets in the liver graft. Moreover, the release of t-PA from the graft results in proteolysis of key platelet receptors. In the postoperative period, thrombocytopenia is common, mainly due to platelet activation and consumption following graft reperfusion Platelet count and coagulation factors usually increase steadily toward normal levels, if normal synthetic function of the liver is restored in the first few days after transplantation.
The thrombopoietin levels increase significantly on the first day post-LT, following by immature bone marrow megakaryocytes after 3 days and new circulating platelets after 5 days, with normalization of platelet count achieved after 14 days. Persistence of thrombocytopenia can be seen in some patients, which can be ascribed to persistent splenomegaly in some. In adult-to-adult living donor liver transplantation, persistently Thromboelastography is a technique that can provide continuous observation and tracing of all the haemostatic functions that lead to clot formation and dissolution and is becoming a very useful tool during such major surgical interventions.
Common Laboratory Tests for Coagulation in Liver Disease
The controls by using a correction factor that is based on the specific thromboplastin used in the PT measurement. The common INR is not calibrated for use in liver disease, especially cirrhosis patients. This is most evident in the remarkably high interlaboratory variability in liver disease patients, depending on which thromboplastin reagent is purchased for the assay.
Few experts have advised for the use of a 'Liver INR' which uses cirrhosis patients as controls and a standard thromboplastin reagent, but this calibration is economically and logistically difficult and widespread adoption is only a theoretical possibility [27] . The PT/INR measures the classic procoagulant extrinsic pathway, is inexpensive, quick and widely available. It also shows good correlation with the severity of the liver disease but has high interlaboratory variability and is not very good at predicting bleeding episodes. The activated partial thromboplastin time (APTT) measures the classic procoagulant intrinsic pathway and is also widely available and inexpensive. It can also detect congenital factor deficiencies but usually do not reflect on hepatic dysfunction; it has been usually found to be normal or nearly normal in liver diseases. Platelet count, even though widely available and quick and inexpensive, does not reflect platelet function in chronic liver disease. It is highly reproducible and has some correlation with bleeding at low levels (below 50x10^9/cumm) but is also not predictive of bleeding at higher levels. Platelet function assays (measures primary hemostasis) are useful in providing generalized platelet function in the wake of normal thrombocyte counts. Most assays assume normal platelet and are not calibrated for thrombocytopenia in liver disease patients and hence not useful in this subgroup. Bleeding time assessment (measures mucosal and skin hemostasis) even though gives a better view of the whole hemostatic system, does not predict procedural bleeding and is time consuming and produces patient discomfort and not widely accepted. vWF complex levels which measures primary hemostasis reflects severity of liver disease and offers prognostic value in liver disease. Lower levels indicate the need for platelet transfusion, but are not generally validated in predicting bleeding episodes in cirrhosis patients and its complex relationship with ADAMTS13 makes inference difficult in cirrhosis patients [28] . Fibrinogen (measures fibrinolysis) levels of more than 100mg/dL suggest adequate fibrinogen for initiation of coagulation. Low levels are suggestive of hyperfibrinolysis but are also common in stable non bleeding cirrhosis patients. It is also an acute phase reactant and in the presence of systemic infection in cirrhosis or in inflammatory conditions (as cirrhosis is one such entity), the values may be erroneous. It is not predictive of DIC in cirrhosis due to this fact. Individual Factor level assays measure the procoagulant and anticoagulant system and can give a relative sense for factor deficiencies on either system. These levels are affected by acute clotting and other disease processes and there is no clear relationship to bleeding or clotting risks in cirrhosis patients; also shows significant laboratory variations and are expensive. Euglobulin lysis time is a validated measure of fibrinolysis and can be used as a measure of treatment efficacy in hyperfibrinolysis, but is not widely available [29] .
Newer Modalities of Laboratory Testing of Coagulation Thromboelastography
Thromboelastography Clinical reference values differ between the 2 systems and must be interpreted accordingly.
The use of citrated whole blood is the standard for thromboelastographic systems today.
Before initiation of the test, provide a global assessment of haemostatic function from initial clot formation to clot dissolution, serial TEG measurements can be suggestive of hypocoagulability which may be associated with early rebleeding in cirrhotic patients [32] . The normal TEG tracing in comparison with abnormal tracings is shown in Figure 5 . 
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Thromboelastography In Liver Disease
The first use of TEG in patients with liver disease was to guide pro-hemostatic factor repletion in patients undergoing liver transplantation (LT), where in TEG-guided factor repletion led to a decrease in red blood cell and plasma infusion volumes. 1 unit of platelets decrease the R-time by 0.43 minutes, raise the angle by 1.5°, and raised the maximum amplitude of clot formation by 1.4 mm. The usual recommendations for correction of TEG parameters are 2 units of plasma for an R-time greater than 15 minutes, 10 units of platelets for a maximum amplitude less than 40 mm, and 6 units of cryoprecipitate for an a-angle less than 40-45°. TEG has also been used during LT to monitor and treat hyperfibrinolysis with eaminocaproic acid and aprotinin, also leading to a decrease in transfusion requirements.
Intraoperative TEG has also been used to guide repletion of factor IX in a patient with hemophilia B undergoing LT for cirrhosis due to hepatitis C virus infection [3, 34] . The blood product transfusion protocol based on TEG and laboratory parameters are as shown in Figure   6 . [35] .
Sonoclot And Platelet Function Analysis In Liver Disease
Sonoclot Coagulation and Platelet Function Analyzer (Sienco Inc., Arvada, CO, USA) was Sonoclot is more durable than TEG, requiring fewer repetitions. Also, Sonoclot is considered more specific as it represents the initial clot formation and reflects clotting factor defects whereas TEG reaction time (R) gives information about a more mature and developed fibrin clot. Sonoclot assay is quite an accurate tool, comparable to TEG for assessing global coagulopathic disorders in liver disease [37] . The normal SONOCLOT signature and variables are as shown in Figure 7 . MP TF assay. In patient of cirrhosis, MP procoagulant assay is highly experimental and not validated as of yet [40] .
Clinical Aspects of Coagulopathy in Liver Disease Bleeding
The various important clinical aspects of coagulation dysfunction in patients of liver disease, especially cirrhosis is given briefly as follows [41] .
Variceal bleeding
Gastrointestinal bleeding is mainly haemodynamic in its mechanisms and is related to portal hypertension. Risk factors for developing variceal bleeding include advanced Child-Pugh class, large varices and the presence of red wale markings. High levels of D-dimer and t-PA have been described as significant laboratory markers of risk of variceal bleeding, independently of other laboratory markers and severity of liver disease. In decompensated cirrhotic patients, variceal bleeding is also the main coagulopathy-related problem, representing 50% of all hemorrhagic events. Even though variceal bleeding is portal pressure related, the platelet plug sign suggests a possible role of hemostatic system in re-bleeding risk.
The treatment is primarily by endoscopic or by measures to decrease portal hypertension through drug therapy. The role of procoagulants is currently still not established.
Intracerebral Haemorrhage
The prevalence of spontaneous intracerebral hemorrhage in hospitalized cirrhotic patients, is low (0.8% for all aetiologies, 80.3% in virus-related and 1.8% in alcohol-related groups), and it is reported not to be related to severity of liver cirrhosis (CTP) or prolonged PT. Alcoholrelated cirrhotic patients have the shortest time interval between diagnosis of liver disease and hospitalization due to brain haemorrhage and heavy drinkers have a significantly higher risk of hemorrhagic stroke than non-heavy drinkers. Rarely, cerebral metastasis bleeding may be the initial manifestation of hepatocellular carcinoma in cirrhotic patients.
Portal hypertensive gastropathy
It is primarily a mechanically driven pathology associated with high portal pressures, as suggested by response to TIPS or beta blocker therapy. Portal decompression by either mechanical or pharmacological means is usually the management.
Gastric vascular ectasia
It is a microvascular disorder and the relationship to hemostatic defects is not well explored in this condition. The management is sometimes difficult with sometimes being refractory to all measures and there is no definitive therapy and is often treated with endoscopic cauterization procedures.
Abdominal Paracentesis/ Pleurocentesis
Common laboratory indices of coagulation are of no value in predicting bleeding episodes related to these interventional procedures. No prophylactic measures need to be undertaken to prevent bleeding related to these procedures as they may result in excessive and wasteful transfusion which may adversely affect the patient at average risk. Paracentesis has a 0.2% incidence of severe haemorrhage, with a death rate of 0.016%. Paracentesis-related bleeding risk has not been found to be associated with a PT prolonged up to twice the midpoint of normal (highest noted at INR of 8.8) or with a platelet count of even at 19,000 per cumm.
Percutaneous Liver Biopsy
Major bleeding in this situation is not well-predicted by conventional coagulation indices. The presence of hyperfibrinolysis can be a marker for delayed massive bleeding in patients of cirrhosis. Sonoclot and TEG can be helpful in this situation. The incidence of biopsy associated bleeding in patients with histological diagnosis of cirrhosis is 0.7%; neither PT nor prolonged APTT and thrombocytopenia are reliable predictors of biopsy related bleeding.
Other risk factors in cirrhosis patients for bleeding due to interventional procedures include those without were lower albumin and presence of large varices. 
Generalized Mucosal Bleeding
The presence of generalized bleeding from mucosal surfaces especially gums or gastrointestinal tract can be indicative of the presence of a fibrinolytic disorder.
Contusions and Cutaneous Hematomas
In cirrhosis patients, these can lead to compartment syndromes and represent significant blood loss. The development of severe hematomas suggests the presence of a net bleeding diathesis and warrants careful investigation in this group of patients. Tests of global coagulation assessment are more favourable in this situation than the conventional coagulation parameters.
Tooth Extractions
These are frequently performed in patients undergoing liver transplantation and is associated with delayed bleeding in a significant proportion of patients. The presence of high fibrinolytic activity in oral cavity suggests a role for antifibrinolytic therapy in this setting.
Central Venous Cannulation.
Bleeding complications during central venous canulation in cirrhotic patients are rare and can be safely performed in patients with liver disease and abnormal coagulation tests, even if the INR is 1.5 or more. Although the occurrence of severe bleeding complications is very low for both for subclavian and internal jugular routes of access, in order to prevent minor bleedings and vascular complications, cannulations should to be performed by experienced personnel with ultrasound guidance.
Other conditions that lead to clinically relevant bleeding in cirrhosis patients include tracheostomy procedures in decompensated patients, which maybe a necessity at one point. 72 hours of therapy. The bleeding risk in patients with ALF was traditionally estimated to be higher than that of cirrhosis, which was thought to be related to the increased severity of hemostatic alterations. Currently bleeding is an uncommon cause of death in ALF patients.
Spontaneous and clinically significant bleeding in ALF is rare in current practice. Routine prophylactic correction of coagulation is currently discouraged in ALF because of uncertain benefit and the potential harm of volume expansion with plasma which may worsen intracranial hypertension or products such as recombinant Factor VIIa (rFVIIa) which carry thrombotic risks. The risk of potentially fatal intracranial bleeding with placement of an ICP monitor, varies with the depth of the monitor device, but ranges from 3% to 10%. In this setting, guidelines recommend cautious use of prophylactic rFVIIa which is evidence based and not well validated [42] .
Thrombosis
The incidence of arterial thrombosis, including coronary artery disease and ischemic stroke is thought to be lower in cirrhosis compared to the general population. A well-established exception is NASH-related cirrhosis where the incidence of arterial thrombosis is increased. anticoagulant drugs has been shown to attenuate progression of fibrosis in animal models [45] . (Table 1) Patients with cirrhosis will experience the development of varices at a rate of about 8% per precipitate anasarca, and expose the patient to events such as transfusion-related acute lung injury, cardiogenic pulmonary edema, and iatrogenic increases in portal pressures leading to rebleeding risks [47] . Under controlled trails, it was recommended that recombinant activated factor VII cannot be recommended for general use. An algorithm based on TEG for blood product transfusions and the corresponding blood product dosing in shown in Figure 8 and Figure 9 . There are no good measures of bleeding risk before invasive procedures that are currently available to the practicing clinician. Practically, one can recommend that truly elective procedures should be delayed during acute events (acute infection, severe acute alcoholic hepatitis, and uraemia) that might upset the rebalanced hemostatic system in cirrhosis patients. Decisions to proceed with elective or semielective procedures should not be solely based on the INR and platelet counts but on the severity of comorbidities of the patient, the urgency of the procedure, the accessibility of the procedural site to mechanical hemostasis maneuvers, and the ability to detect bleeding at the site early in the hemorrhage. If the policy of the treating unit is for prophylactic transfusion, then in cirrhosis patients the INR should not be used as a sole measure of bleeding risk, and physiologically it would be more appropriate to achieve a platelet count greater than 50-60 x 109/L for high-risk procedures by using platelet transfusions [48] . The MELD is a validated tool for predicting surgical aware that persistent postoperative wound, mucosal and/or puncture site bleeding could be a sign of hyperfibrinolysis, which warrants more specific therapy. The use of desmopressin in compensated cirrhotics showed that it shortened the bleeding time and partial thromboplastin time with increases in factor VIII and vWF, but it was not efficacious in controlling variceal bleeding or reducing blood loss in patients undergoing liver transplantation or liver resection.
Management Considerations of Bleeding in Liver Disease
This indicated that normalization of bleeding time does not necessarily diminish bleeding risk and bleeding time is not a reliable prognostic factor of significant bleeding [49] . The combination of desmopressin and terlipressin increased the rebleeding rate compared with terlipressin alone in a study. So the concomitant use of these two agents together should be cautious [50] . The different modalities of microvascular bleeding management in cirrhosis patients is shown in Table 1 . platelet function in patients with hepatitis C is the administration of a thrombopoietin analog (Eltrombopag) which has been shown to substantially increase the platelet count in these patients. With Eltrombopag, the chances of hypercorrection of the platelet count exists and in some patients, a theoretical risk of thrombosis occurs, especially in light of the highly elevated vWF levels [52] . 
Management Considerations in Thrombotic Events in Liver Disease
Cirrhotic patients may need thromboprophylaxis or anticoagulation in certain clinical scenarios, especially those involving an additional thrombotic risk. Antifactor Xa activity negatively correlates with the severity of the liver disease, and a positive correlation is seen with antithrombin-III levels and antifactor-Xa value. Antithrombin-III itself negatively correlates with the severity of liver disease [53] . has been reported to achieve complete recanalization of the portal vein within 2-11 days, with no significant increase in rebleeding incidence [55] . Thromboembolism has been reported to behigher between cirrhotic patients who do not receive thromboprophylaxis, and thromboprophylaxis with LMWH has not shown any increase the relative risk of bleeding post hepatectomy in cases of cirrhosis with hepatocellular carcinoma. In a randomized non- in the light of efficacy and safety need to be sensibly applied in this sub group of patients so as to improve outcomes.
